1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
Meiji Holdings Co., Ltd.

Meiji Holdings Co., Ltd.

MEJHF
Meiji Holdings Co., Ltd.US flagOther OTC
20.25
USD
- -
- -
5.49BMarket Cap
Meiji Holdings Co., Ltd.
MEJHF
(Other OTC)

Recent

price

20.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
3,769.27
3,764.44
3,823.22
3,897.07
3,942.82
4,155.98
4,221.99
4,274.23
4,324.76
4,317.95
4,107.01
7,031.02
3,784.86
3,962.57
4,227.35
- -
2,014.55
Revenue per Share
32.41
23.09
56.49
64.7
104.89
212.53
206.55
211.08
213.3
232.04
226.26
607.24
247.38
181.64
186.08
- -
81.94
Basic EPS, GAAP
59.32
-26.25
43.96
57.06
75.18
213.28
106.94
127.45
140.87
148.13
192.24
238.47
45.76
195.49
45.26
- -
193.34
Free Cash Flow per Basic Share
29.77
19.9
19.89
19.92
19.95
28.67
53.59
61.43
68.58
72.34
77.35
165.86
87.68
94.79
98
- -
49
Dividend per Share
685.76
693.97
731.15
777.18
859.65
1,045.56
1,199.02
1,365
1,509.91
1,667.36
1,815.32
4,096.34
2,252.2
2,351.96
2,488.11
- -
2,408.58
Book Value per Share
962.86
985.67
1,061.81
1,086.06
1,183.67
1,324.66
1,465.41
1,627.98
1,886.17
2,010.48
2,217.14
4,822.5
2,600.6
2,748.52
2,829.8
- -
2,717.55
Tangible Book Value per Share
295
295
295
295
294
294
294
290
290
290
290
144
281
279
273
271
278
Basic Weighted Avg Shares
1,111,000
1,109,275
1,126,520
1,148,076
1,161,152
1,223,746
1,242,480
1,240,860
1,254,380
1,252,706
1,191,765
1,013,092
1,062,157
1,105,494
1,154,074
- -
559,447
Sales/Revenue/Turnover
2.7
1.82
2.3
3.18
4.44
6.36
7.11
7.63
7.84
8.2
8.9
9.17
7.1
7.63
7.34
- -
7.13
Operating Margin (%)
41,682
41,119
40,945
41,110
42,519
43,854
47,477
48,152
44,674
46,231
48,426
50,118
53,590
55,317
54,979
- -
28,450
Depreciation Expense
9,552
6,805
16,646
19,060
30,891
62,580
60,786
61,278
61,868
67,318
65,655
87,497
69,424
50,675
50,800
- -
22,754
Net Income, GAAP
46.52
51.67
33.18
43.62
35.32
33.2
31.38
31.97
32.75
28.64
32.08
28.08
25.06
38.62
34.43
- -
40.91
Effective Tax Rate (%)
0.86
0.61
1.48
1.66
2.66
5.11
4.89
4.94
4.93
5.37
5.51
8.64
6.54
4.58
4.4
- -
4.07
Profit Margin (%)
343
-29,969
31,447
67,605
53,443
86,223
63,516
88,575
129,943
160,365
173,042
168,800
204,661
240,684
233,688
- -
231,440
Working Capital
83,821
56,401
108,285
134,630
133,889
97,997
48,923
69,353
82,788
75,890
84,525
53,039
49,496
27,596
22,423
- -
24,236
LT Debt
293,530
298,490
320,609
328,121
380,300
419,150
457,190
495,176
560,630
597,570
659,357
713,019
751,309
787,790
791,782
- -
774,550
Total Equity
3.22
1.96
3.32
3.84
5.78
8.6
10.14
10.42
9.95
10.36
9.6
8.36
6.89
6.16
6.5
- -
2.69
Return on Invested Capital (%)
2.65
1.84
4.14
4.6
6.75
13.09
12.74
12.05
10.92
10.78
9.55
12.04
9.36
6.45
6.29
- -
2.86
Return on Capital (%)
4.76
3.35
7.93
8.58
12.81
22.31
18.4
16.36
14.83
14.61
12.99
15.67
11.36
7.87
7.61
- -
3.46
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
22,330
- -
53,466
LT Borrowings
27,596
- -
24,236
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
279
- -
271
Market Capitalization
930,104
1,013,444
904,918

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
563,029
- -
540,922
Cash, Cash Equivalents & STI
106,858
- -
78,810
Accounts Receivable, Net
202,239
- -
199,995
Inventories
199,368
- -
224,400
Total Current Liabilities
322,345
- -
309,482
Payables & Accruals
- -
- -
- -
ST Debt
22,330
- -
53,466
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
262,734
283,313
286,956
272,491
1,105,494
2025
- -
- -
- -
- -
1,154,074
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
41.59
- -
- -
- -
181.64
2025
- -
- -
- -
- -
186.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
46.73
- -
- -
- -
94.79
2025
- -
- -
- -
- -
98
2026
- -
- -
- -
- -
- -
Similar Companies
Komo Plant Based Foods Inc. (YUM.CN)
Nightfood Holdings, Inc. (NGTF)
Crumbs Bake Shop, Inc. (CRMBQ)
PT Indofood CBP Sukses Makmur Tbk (ICBP.JK)
Savencia S.A. (0DTK.L)
Global Diversified Marketing Group, Inc. (GDMK)
Business
Meiji Holdings Co., Ltd. Meiji Holdings Co., Ltd. is a Japan-based pure holding company that oversees subsidiaries engaged in the food and pharmaceuticals sectors; it manages the manufacture and sale of dairy products including yogurt, milk, cheese, butter, ice cream and beverages; confectionery such as chocolate, gummy candy, gum and snacks; nutritional products like protein supplements, infant formula, health foods and sports nutrition; as well as pharmaceuticals encompassing ethical drugs for infectious diseases, central nervous system disorders and immune inflammatory conditions, vaccines, blood plasma products, generic drugs, animal health products and contract manufacturing services. Headquartered in Tokyo at 2-4-16 Kyobashi, Chuo-ku, the company was established on April 1, 2009, through the integration of Meiji Seika and Meiji Dairies, with roots tracing back to 1916; its key subsidiaries include Meiji Co., Ltd. for food operations, Meiji Seika Pharma Co., Ltd. for pharmaceuticals and KM Biologics Co., Ltd. for biologics and vaccines, serving domestic and international markets across Asia, Europe and the Americas with approximately 17,270 employees as of March 2024. The group operates through two primary segments, with the food business accounting for around 81% of sales and focusing on wellness-oriented products utilizing lactic acid bacteria, milk and cacao research; the pharmaceuticals segment, representing 19% of sales, emphasizes infectious disease countermeasures including antibacterial drugs and next-generation mRNA vaccines like KOSTAIVE. Meiji Holdings pursues food-pharmaceutical synergies and open innovation under its 2026 Medium-Term Business Plan, targeting mid-to-high single-digit operating income growth, 20% overseas sales ratio and ROE of 10%, while advancing sustainability initiatives such as sustainable cacao procurement via Meiji Cocoa Support and dairy farming support. Recent strategic changes include a January 2024 licensing agreement with Seqirus Inc. for the ARCT-154 self-amplifying mRNA COVID-19 vaccine and future variants in Japan; the July 2018 acquisition of KM Biologics Co., Ltd.; and a November 2025 board resolution to transfer its KM Biologics shares to Meiji Seika Pharma via absorption-type company split effective January 2026 to enhance pharmaceutical integration, R&D, manufacturing and global expansion in infectious diseases.